Pharming Group (PHG) Price & Analysis

0 Followers

PHG Stock Chart & Stats

€9.55

€0.10(0.93%)

At close: Jul 24 4:00 PM EDT

€9.55

€0.10(0.93%)

Day’s Range― - ―

52-Week Range€8.05 - €17.40

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€656.25M

Enterprise Value€1.08K

Total Cash (Recent Filing)€158.28M

Total Debt (Recent Filing)€113.30M

Price to Earnings (P/E)71.9

Beta0.82

Next Earnings

Nov 05, 2026

EPS Estimate

0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.14

Shares Outstanding70,778,120

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-3.60

Price to Book (P/B)4.55

Price to Sales (P/S)3.35

P/FCF Ratio23.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€32.92

Price Target Upside244.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.17

Revenue Forecast (FY)€337.83M

Bulls Say, Bears Say

Bulls Say

Joenja Commercial GrowthJoenja is showing strong commercial traction, with revenue and treated-patient growth supported by international expansion and pediatric label opportunities. This broadens Pharming’s chronic rare-disease revenue base and could make growth more durable as additional markets and eligible patients are reached.

Improved Profitability And Gross MarginsThe return to positive earnings alongside very high gross profitability indicates that Pharming’s approved products can support attractive economics once commercial scale is established. Although bottom-line profitability is still modest, this foundation can help fund operations and product development over the next several quarters.

Pediatric Regulatory ExpansionFDA acceptance and Priority Review create a defined regulatory pathway to serve lower-weight children aged four and older with APDS. If approved, the dosing expansion could increase Joenja’s eligible population, reinforce its position in pediatric care, and support longer-term patient growth.

Bears Say

Weak Top-line TrajectoryThe reduced revenue outlook indicates that Joenja’s rapid growth is not yet fully offsetting weakness elsewhere in the portfolio. A near-flat overall sales trajectory limits operating leverage, slows progress toward stronger earnings, and leaves the company dependent on successful execution of future commercial expansions.

RUCONEST Competitive PressureRUCONEST remains a major commercial product but is facing U.S. competitive pressure, planned withdrawal from some international markets, and channel normalization. Continued erosion in this established franchise could offset Joenja gains and make Pharming’s consolidated revenue and cash generation less predictable.

Cash Flow And R&D PressureOperating cash outflows combined with substantially higher R&D investment are likely to weigh on near-term earnings and cash conversion. Although management cites funding capacity, sustained development spending increases the need for Joenja growth and pipeline progress to translate into stronger long-term returns.

Pharming Group News

Pharming announces FDA acceptance, Priority review of sNDA for Joenja

Pharming (PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application seeking...

3d ago

PHAR

Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright

Initial Phase 2 data for Pharming’s (PHAR) Leniolisib in genetically defined PIDs beyond APDS are encouraging, showing improvements...

6d ago

PHAR

Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs

Pharming (PHAR) announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib...

6d ago

PHAR

FDA approves Joenja tablets for children aged 4-11 with APDS

The FDA announced that it has approved Joenja tablets as the first treatment for activated phosphoinositide 3-kinase delta...

17d ago

PHAR

Pharming price target raised to $38 from $37 at Canaccord

Canaccord raised the firm’s price target on Pharming (PHAR) to $38 from $37 and keeps a Buy rating...

2M ago

PHAR

Pharming cuts FY26 revenue view to $375M-$395M from $405M-$425M

Consensus $404.01M. Cuts FY26 operating expenses view to $315M-$320M from $330M-$335M. Published first on TheFly – the ultimate...

2M ago

PHAR

Pharming reports Q2 EPS 2c, consensus 6c

Reports Q2 revenue $90.2M, consensus $99.52M. CEO, Fabrice Chouraqui, commented: “While we have lowered our full-year revenue guidance,...

2M ago

PHAR

Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with...

3M ago

PHAR

Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Pharming Group yesterday and set a price target...

3M ago

PHAR

Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS

Pharming Group ( ($PHAR) ) just unveiled an announcement. On June 4, 2026, Pharming Group announced that the...

4M ago

PHAR

Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda

Pharming Group ( ($PHAR) ) just unveiled an announcement. On May 28, 2026, Pharming Group shareholders approved all...

4M ago

PHAR

Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Pharming Group, retaining the price target of...

4M ago

PHAR

Pharming Wins EU Green Light for Joenja, First Approved Treatment for APDS

Pharming Group ( ($PHAR) ) has issued an update. On May 22, 2026, Pharming announced that the European...

4M ago

PHAR

Pharming’s Joenja granted marketing authorization by European Commission

Pharming (PHAR) Group announced that the European Commission has granted marketing authorization for Joenja, an oral, selective phosphoinositide...

4M ago

PHAR

PHG FAQ

What was Pharming Group’s price range in the past 12 months?

Pharming Group lowest stock price was €8.05 and its highest was €17.40 in the past 12 months.

What is Pharming Group’s market cap?

Pharming Group’s market cap is €656.25M.

When is Pharming Group’s upcoming earnings report date?

Pharming Group’s upcoming earnings report date is Nov 05, 2026 which is in 38 days.

How were Pharming Group’s earnings last quarter?

Pharming Group released its earnings results on Jul 30, 2026. The company reported €0.017 earnings per share for the quarter, missing the consensus estimate of €0.055 by -€0.038.

Is Pharming Group overvalued?

According to Wall Street analysts Pharming Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharming Group pay dividends?

Pharming Group does not currently pay dividends.

What is Pharming Group’s EPS estimate?

Pharming Group’s EPS estimate is 0.14.

How many shares outstanding does Pharming Group have?

Pharming Group has 70,778,120 shares outstanding.

What happened to Pharming Group’s price movement after its last earnings report?

Pharming Group reported an EPS of €0.017 in its last earnings report, missing expectations of €0.055. Following the earnings report the stock price went down -25.463%.

Which hedge fund is a major shareholder of Pharming Group?

Currently, no hedge funds are holding shares in DE:PHG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharming Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

4.87%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharming Group

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Pharming Group (PHG) Earnings & Revenues

Historic Earnings Reports

PHG Company Deck

PHG Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented a mixed picture: strong commercial momentum for Joenja (robust percentage growth, geographic and pediatric expansion) and encouraging underlying RUCONEST demand indicators (active patient base ~93%, sequential revenue rebound) are offset by near-term headwinds — RUCONEST year-over-year revenue declines, a $30M revenue guidance reduction, operating cash outflows, and a manufacturing inventory impairment. Management emphasized cost discipline, positive operating profit in Q2, sufficient cash to fund the pipeline, and several upcoming clinical catalysts (leniolisib Phase II readouts in Q4, napazimone in 2027) that could materially change the trajectory. Given the balance of meaningful near-term challenges against several concrete growth drivers and pipeline milestones, the overall tone is cautious and balanced.View all DE:PHG earnings summaries

PHG Stock 12 Month Forecast

Average Price Target

€32.92

▲(244.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","34":"€34","13.75":"€13.75","20.5":"€20.5","27.25":"€27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.36060698,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€33.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.921651624999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€32.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.48269627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.75,20.5,27.25,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.35,11.196969767692307,13.043939535384615,14.890909303076922,16.73787907076923,18.58484883846154,20.431818606153847,22.278788373846155,24.125758141538462,25.97272790923077,27.819697676923077,29.666667444615385,31.513637212307692,{"y":33.36060698,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.35,11.163203971153845,12.976407942307691,14.789611913461536,16.60281588461538,18.41601985576923,20.229223826923075,22.042427798076922,23.855631769230765,25.66883574038461,27.482039711538455,29.295243682692302,31.10844765384615,{"y":32.921651624999996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.35,11.129438174615384,12.908876349230768,14.688314523846152,16.46775269846154,18.247190873076924,20.026629047692307,21.80606722230769,23.585505396923075,25.36494357153846,27.144381746153847,28.923819920769226,30.703258095384612,{"y":32.48269627,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >